Mi­rati steps on the gas with KRAS in­hibitor, look­ing to claim sec­ond ap­proval be­hind Am­gen's Lumakras

Am­gen beat Mi­rati to the fin­ish line with the first-ever ap­proved KRAS in­hibitor back in May. But Mi­rati’s pick­ing up the pace and says it could be look­ing to carve out a space on the mar­ket by the end of the year with what it thinks is the bet­ter of the two da­ta sets as monother­a­py.

The FDA has grant­ed break­through des­ig­na­tion to Mi­rati’s ada­gra­sib in non-small cell lung can­cer pa­tients with the KRAS-G12C mu­ta­tion fol­low­ing pri­or ther­a­py, the com­pa­ny said on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER